The Application and Efficacy of Medication Safety Officer-Based Multidisciplinary Management in Reducing Adverse Drug Reaction and Improving Intravenous Management.
Xiaolu Zhang, Meixing Yan, Xianfeng Qu, Yang Li, Lu Liu, Chang Liu
{"title":"The Application and Efficacy of Medication Safety Officer-Based Multidisciplinary Management in Reducing Adverse Drug Reaction and Improving Intravenous Management.","authors":"Xiaolu Zhang, Meixing Yan, Xianfeng Qu, Yang Li, Lu Liu, Chang Liu","doi":"10.2147/RMHP.S504874","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intravenous (IV) therapy is a common treatment but is associated with high rates of medication errors and adverse events, especially in children. In China, most public hospitals have halted adult outpatient IV services, but pediatric IV management remains a challenge. This study evaluates the effectiveness of medication safety officer (MSO)-based multidisciplinary management on managing IV fluids in children's outpatient and emergency departments, aiming to reduce adverse drug reaction (ADR) and standardize IV infusion management.</p><p><strong>Methods: </strong>Implementing MSO-based multidisciplinary management integrates multidisciplinary supervision, information system optimization, and fostering medication safety culture. We assessed its effectiveness by examining indicators such as the utilization of IV infusion, the unreasonable rate of IV infusion prescriptions, the incidence of IV infusion ADR and medication expenses among outpatient and emergency department patients.</p><p><strong>Results: </strong>Although peak pediatric influenza and mycoplasma infections led to increased rates of IV fluids after liberalizing control of COVID-19 epidemic, there was a notable decrease in the percentage of antimicrobials in IV infusion (<i>P</i> < 0.001). More importantly, the unreasonable rate of IV infusion prescriptions and the incidence of ADR to IV infusion have significantly decreased, dropping from 7.72% and 0.04% to 4.45% and 0.01%, respectively (P < 0.001). Furthermore, both average cost of drugs and per capita cost of using IV drugs significantly decreased (P < 0.001).</p><p><strong>Conclusion: </strong>The implementation of MSO-based multidisciplinary management can effectively improve the irrational use of IV fluids, reduce ADR and medical expenses in pediatric outpatient and emergency departments, to ensure children's medication safety.</p>","PeriodicalId":56009,"journal":{"name":"Risk Management and Healthcare Policy","volume":"18 ","pages":"891-900"},"PeriodicalIF":2.7000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11910933/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Risk Management and Healthcare Policy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/RMHP.S504874","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Intravenous (IV) therapy is a common treatment but is associated with high rates of medication errors and adverse events, especially in children. In China, most public hospitals have halted adult outpatient IV services, but pediatric IV management remains a challenge. This study evaluates the effectiveness of medication safety officer (MSO)-based multidisciplinary management on managing IV fluids in children's outpatient and emergency departments, aiming to reduce adverse drug reaction (ADR) and standardize IV infusion management.
Methods: Implementing MSO-based multidisciplinary management integrates multidisciplinary supervision, information system optimization, and fostering medication safety culture. We assessed its effectiveness by examining indicators such as the utilization of IV infusion, the unreasonable rate of IV infusion prescriptions, the incidence of IV infusion ADR and medication expenses among outpatient and emergency department patients.
Results: Although peak pediatric influenza and mycoplasma infections led to increased rates of IV fluids after liberalizing control of COVID-19 epidemic, there was a notable decrease in the percentage of antimicrobials in IV infusion (P < 0.001). More importantly, the unreasonable rate of IV infusion prescriptions and the incidence of ADR to IV infusion have significantly decreased, dropping from 7.72% and 0.04% to 4.45% and 0.01%, respectively (P < 0.001). Furthermore, both average cost of drugs and per capita cost of using IV drugs significantly decreased (P < 0.001).
Conclusion: The implementation of MSO-based multidisciplinary management can effectively improve the irrational use of IV fluids, reduce ADR and medical expenses in pediatric outpatient and emergency departments, to ensure children's medication safety.
期刊介绍:
Risk Management and Healthcare Policy is an international, peer-reviewed, open access journal focusing on all aspects of public health, policy and preventative measures to promote good health and improve morbidity and mortality in the population. Specific topics covered in the journal include:
Public and community health
Policy and law
Preventative and predictive healthcare
Risk and hazard management
Epidemiology, detection and screening
Lifestyle and diet modification
Vaccination and disease transmission/modification programs
Health and safety and occupational health
Healthcare services provision
Health literacy and education
Advertising and promotion of health issues
Health economic evaluations and resource management
Risk Management and Healthcare Policy focuses on human interventional and observational research. The journal welcomes submitted papers covering original research, clinical and epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, and extended reports. Case reports will only be considered if they make a valuable and original contribution to the literature. The journal does not accept study protocols, animal-based or cell line-based studies.